Orient Biotech(SH:688298) Xin Lang Cai Jing·2025-11-12 02:53Core Viewpoint - Oriental Bio has experienced a stock price increase of 5.11% on November 12, reaching 28.57 CNY per share, with a total market capitalization of 5.76 billion CNY, indicating a cumulative increase of 4.34% over three consecutive days [1] Company Overview - Zhejiang Oriental Gene Biological Products Co., Ltd. was established on December 1, 2005, and went public on February 5, 2020. The company specializes in the research, production, and sales of in vitro diagnostic products, with 97.99% of its revenue coming from diagnostic reagents and 2.01% from other supplementary sources [1] Shareholder Analysis - The top circulating shareholder of Oriental Bio includes a fund from Rongtong Fund, which reduced its holdings by 1.7 million shares in the third quarter, now holding 2.8 million shares, representing 1.39% of the circulating shares. The fund has gained approximately 3.89 million CNY in floating profit today and 3.16 million CNY during the three-day increase [2] Fund Performance - The Rongtong Health Industry Flexible Allocation Mixed A/B Fund (000727) has a total scale of 1.816 billion CNY and has achieved a year-to-date return of 15.36%, ranking 5146 out of 8147 in its category. Over the past year, it has returned 1.86%, ranking 7321 out of 8056, and since inception, it has returned 178.7% [2] Fund Holdings - The Rongtong Health Industry Flexible Allocation Mixed A/B Fund (000727) has Oriental Bio as its tenth largest holding, with 2.98% of the fund's net value allocated to this stock. The fund manager, Wan Minyuan, has been in position for 9 years and 81 days, with the best return during his tenure being 143.42% and the worst being -21.5% [3]